Jefferies Maintains Bullish Stance on Dynavax (DVAX) On Heplisav CKD Data Update

Article Stock Quotes (1) Comments (1)

Jefferies reiterated their Buy and $6 price target on Dynavax Technologies (NASDAQ: DVAX) after the company provided an incrementally positive update of previous Phase 3 CKD data and from new CKD booster data.

The firm comments, "We remain bullish on the diabetes opportunity and the prospects for a broad label indication for Heplisav. DVAX remains on track to file in the US in May. We continue to believe that DVAX represents attractive risk-reward for investors with significant upside potential on a FDA panel in early 2013."

For an analyst ratings summary and ratings history on Dynavax Technologies click here. For more ratings news on Dynavax Technologies click here.

Shares of Dynavax Technologies closed at $4.70 yesterday, with a 52 week range of $1.75-$4.79.

---

Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW

---

*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here

---

---

You May Also Be Interested In

• Morgan Stanley Maintains Bullish Stance on Walter Energy (WLT)
• Brean Capital Downgrades Tetra Tech (TTEK) to Hold
• Gabelli Downgrades Nexstar Broadcasting Group (NXST) to Hold

Create E-mail Alert Related Categories

Analyst Comments

Related Entities

Jefferies & Co

Comments

Add Your Comment

Name

Subject

Body

Share on Facebook

Verification
can't see the text?
click here to refresh the image.
what's this?